GTHX Stock Summary and Trading Ideas (G1 Therapeutics | NASDAQ:GTHX)

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.

G1 Therapeutics trades on the NASDAQ stock market under the symbol GTHX.

As of April 23, 2024, GTHX stock price climbed to $4.20 with 191,526 million shares trading.

GTHX has a beta of 2.16, meaning it tends to be more sensitive to market movements. GTHX has a correlation of 0.05 to the broad based SPY ETF.

GTHX has a market cap of $212.57 million. This is considered a Small Cap stock.

Last quarter G1 Therapeutics reported $15 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.06.

In the last 3 years, GTHX stock traded as high as $24.12 and as low as $1.08.

The top ETF exchange traded funds that GTHX belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

GTHX has outperformed the market in the last year with a return of +55.6%, while the SPY ETF gained +24.4%. In the last 3 month period, GTHX beat the market returning +13.2%, while SPY returned +5.0%. However, in the most recent 2 weeks GTHX has underperformed the stock market by returning -11.9%, while SPY returned -2.5%.

GTHX support price is $3.90 and resistance is $4.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GTHX stock will trade within this expected range on the day.